Literature DB >> 18264109

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens.

Yan Zheng1, Patricia A Valdez, Dimitry M Danilenko, Yan Hu, Susan M Sa, Qian Gong, Alexander R Abbas, Zora Modrusan, Nico Ghilardi, Frederic J de Sauvage, Wenjun Ouyang.   

Abstract

Infections by attaching and effacing (A/E) bacterial pathogens, such as Escherichia coli O157:H7, pose a serious threat to public health. Using a mouse A/E pathogen, Citrobacter rodentium, we show that interleukin-22 (IL-22) has a crucial role in the early phase of host defense against C. rodentium. Infection of IL-22 knockout mice results in increased intestinal epithelial damage, systemic bacterial burden and mortality. We also find that IL-23 is required for the early induction of IL-22 during C. rodentium infection, and adaptive immunity is not essential for the protective role of IL-22 in this model. Instead, IL-22 is required for the direct induction of the Reg family of antimicrobial proteins, including RegIIIbeta and RegIIIgamma, in colonic epithelial cells. Exogenous mouse or human RegIIIgamma substantially improves survival of IL-22 knockout mice after C. rodentium infection. Together, our data identify a new innate immune function for IL-22 in regulating early defense mechanisms against A/E bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264109     DOI: 10.1038/nm1720

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  872 in total

1.  IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques.

Authors:  H Xu; X Wang; D X Liu; T Moroney-Rasmussen; A A Lackner; R S Veazey
Journal:  Mucosal Immunol       Date:  2012-06-06       Impact factor: 7.313

2.  A novel immunoregulatory function for IL-23: Inhibition of IL-12-dependent IFN-γ production.

Authors:  Amy N Sieve; Karen D Meeks; Suheung Lee; Rance E Berg
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

3.  Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage.

Authors:  Mizuho Hasegawa; Shoko Yada; Meng Zhen Liu; Nobuhiko Kamada; Raúl Muñoz-Planillo; Nhu Do; Gabriel Núñez; Naohiro Inohara
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 4.  Innate immune signaling in defense against intestinal microbes.

Authors:  Melissa A Kinnebrew; Eric G Pamer
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

5.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 6.  Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity.

Authors:  Peter J Morrison; Sarah J Ballantyne; Marika C Kullberg
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

Review 7.  IL-17+ γδ T cells as kick-starters of inflammation.

Authors:  Pedro H Papotto; Julie C Ribot; Bruno Silva-Santos
Journal:  Nat Immunol       Date:  2017-05-18       Impact factor: 25.606

Review 8.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

Review 9.  The microbiome and regulation of mucosal immunity.

Authors:  Andrew J McDermott; Gary B Huffnagle
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

10.  Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

Authors:  I H Chan; R Jain; M S Tessmer; D Gorman; R Mangadu; M Sathe; F Vives; C Moon; E Penaflor; S Turner; G Ayanoglu; C Chang; B Basham; J B Mumm; R H Pierce; J H Yearley; T K McClanahan; J H Phillips; D J Cua; E P Bowman; R A Kastelein; D LaFace
Journal:  Mucosal Immunol       Date:  2013-11-27       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.